^
Association details:
| Biomarker: | MUC1 elevation |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer
Published date:
05/19/2020
Excerpt:
...progression-free survival and overall survival are worse in cancer antigen 15-3-sensitive breast cancer patients. Thrombocytopenia, Eastern Cooperative Oncology Group-Performance Status, and cancer antigen 15-3 are correlated with progression-free survival and/or overall survival.
DOI:
10.1177/1078155220924088
